Liver transplantation in human immunodeficiency virus-positive patients

Liver Transplantation

Volumn 17, Issue 8, 2011, Pages 881-890

  Joshi, Deepak ^a   O'Grady, John ^a   Taylor, Chris ^a   Heaton, Nigel ^a   Agarwal, Kosh ^a  

^a KING S COLLEGE HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ABACAVIR; ANTIRETROVIRUS AGENT; CALCINEURIN INHIBITOR; CYCLOSPORIN; DARUNAVIR; DIDANOSINE; EFAVIRENZ; EMTRICITABINE PLUS TENOFOVIR DISOPROXIL; FOSAMPRENAVIR; LOPINAVIR PLUS RITONAVIR; METHYLPREDNISOLONE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; NEVIRAPINE; PEGINTERFERON; PREDNISONE; RALTEGRAVIR; RIBAVIRIN; RITONAVIR; SAQUINAVIR; STAVUDINE; STEROID; TACROLIMUS; TIPRANAVIR; ZIDOVUDINE;

ACUTE GRAFT REJECTION; COHORT ANALYSIS; FATTY LIVER; HEPATITIS B; HEPATITIS C; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNOSUPPRESSIVE TREATMENT; LIVER TOXICITY; LIVER TRANSPLANTATION; LONG TERM EXPOSURE; MITOCHONDRIAL TOXICITY; MORBIDITY; MORTALITY; NONALCOHOLIC FATTY LIVER; PRIORITY JOURNAL; REVIEW; TREATMENT OUTCOME;

ANTI-RETROVIRAL AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; EUROPE; HIV INFECTIONS; HIV SEROPOSITIVITY; HUMANS; IMMUNOSUPPRESSION; LIVER FAILURE; LIVER TRANSPLANTATION; PREVALENCE; TREATMENT OUTCOME; UNITED STATES;

EID: 79960824792     PISSN: 15276465     EISSN: 15276473     Source Type: Journal    
DOI: 10.1002/lt.22329     Document Type: Review

References (89)

1. Palella FJ Jr, Delaney KM, Moorman AC, Loveless MO, Fuhrer J, Satten GA, et al. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators. N Engl J Med 1998; 338: 853-860. (Pubitemid 28135961)
2. Weber R, Sabin CA, Friis-Moller N, Reiss P, El-Sadr WM, Kirk O, et al. Liver-related deaths in persons infected with the human immunodeficiency virus: the D:A:D study. Arch Intern Med 2006; 166: 1632-1641. (Pubitemid 44232373)
3. Tzakis AG, Cooper MH, Dummer JS, Ragni M, Ward JW, Starzl TE,. Transplantation in HIV+ patients. Transplantation 1990; 49: 354-358.
4. Dummer JS, Erb S, Breinig MK, Ho M, Rinaldo CR Jr, Gupta P, et al. Infection with human immunodeficiency virus in the Pittsburgh transplant population. A study of 583 donors and 1043 recipients, 1981-1986. Transplantation 1989; 47: 134-140.
5. Prachalias AA, Pozniak A, Taylor C, Srinivasan P, Muiesan P, Wendon J, et al. Liver transplantation in adults coinfected with HIV. Transplantation 2001; 72: 1684-1688. (Pubitemid 33096747)
6. Mocroft A, Brettle R, Kirk O, Blaxhult A, Parkin JM, Antunes F, et al. Changes in the cause of death among HIV positive subjects across Europe: results from the EuroSIDA study. AIDS 2002; 16: 1663-1671. (Pubitemid 34921112)
7. Salmon-Ceron D, Lewden C, Morlat P, Bévilacqua S, Jougla E, Bonnet F, et al. Liver disease as a major cause of death among HIV infected patients: role of hepatitis C and B viruses and alcohol. J Hepatol 2005; 42: 799-805. (Pubitemid 40693195)
8. Rosenthal E, Salmon-Céron D, Lewden C, Bouteloup V, Pialoux G, Bonnet F, et al.; for Mortavic/Mortalité 2005 Study Group. Liver-related deaths in HIV-infected patients between 1995 and 2005 in the French GERMIVIC Joint Study Group Network (Mortavic 2005 study in collaboration with the Mortalité 2005 survey, ANRS EN19). HIV Med 2009; 10: 282-289.
9. Lewden C, Salmon D, Morlat P, Bévilacqua S, Jougla E, Bonnet F, et al.; for Mortality 2000 Study Group. Causes of death among human immunodeficiency virus (HIV)-infected adults in the era of potent antiretroviral therapy: emerging role of hepatitis and cancers, persistent role of AIDS. Int J Epidemiol 2005; 34: 121-130. (Pubitemid 40347381)
10. Koziel MJ, Peters MG,. Viral hepatitis in HIV infection. N Engl J Med 2007; 356: 1445-1454. (Pubitemid 46556329)
11. Merchante N, Girõn-González JA, González-Serrano M, Torre-Cisneros J, García-García JA, Arizcorreta A, et al.; for Grupo Andaluz para el Estudio de las Enfermedades Infecciosas. Survival and prognostic factors of HIV-infected patients with HCV-related end-stage liver disease. AIDS 2006; 20: 49-57. (Pubitemid 41818114)
12. Pineda JA, Romero-Gõmez M, Díaz-García F, Girõn-González JA, Montero JL, Torre-Cisneros J, et al.; for Grupo Andaluz para el Estudio de las Enfermedades Infecciosas and Grupo Andaluz para el Estudio del Hígado. HIV coinfection shortens the survival of patients with hepatitis C virus-related decompensated cirrhosis. Hepatology 2005; 41: 779-789. (Pubitemid 40462940)
13. Low E, Vogel M, Rockstroh J, Nelson M,. Acute hepatitis C in HIV-positive individuals. AIDS Rev 2008; 10: 245-253.
14. Butt AA, Justice AC, Skanderson M, Rigsby MO, Good CB, Kwoh CK,. Rate and predictors of treatment prescription for hepatitis C. Gut 2007; 56: 385-389. (Pubitemid 46579770)
15. Zinkernagel AS, von Wyl V, Ledergerber B, Rickenbach M, Furrer H, Battegay M, et al.; for Swiss HIV Cohort Study. Eligibility for and outcome of hepatitis C treatment of HIV-coinfected individuals in clinical practice: the Swiss HIV Cohort Study. Antivir Ther 2006; 11: 131-142.
16. Pasquier C, Bujan L, Daudin M, Righi L, Berges L, Thauvin L, et al. Intermittent detection of hepatitis C virus (HCV) in semen from men with human immunodeficiency virus type 1 (HIV-1) and HCV. J Med Virol 2003; 69: 344-349. (Pubitemid 36158314)
17. Serpaggi J, Chaix ML, Batisse D, Dupont C, Vallet-Pichard A, Fontaine H, et al. Sexually transmitted acute infection with a clustered genotype 4 hepatitis C virus in HIV-1-infected men and inefficacy of early antiviral therapy. AIDS 2006; 20: 233-240.
18. Götz HM, van Doornum G, Niesters HG, den Hollander JG, Thio HB, de Zwart O,. A cluster of acute hepatitis C virus infection among men who have sex with men - results from contact tracing and public health implications. AIDS 2005; 19: 969-974. (Pubitemid 40834941)
19. Danta M, Brown D, Bhagani S, Pybus OG, Sabin CA, Nelson M, et al.; for HIV and Acute HCV (HAAC) Group. Recent epidemic of acute hepatitis C virus in HIV-positive men who have sex with men linked to high-risk sexual behaviours. AIDS 2007; 21: 983-991. (Pubitemid 46684329)
20. Bräu N, Salvatore M, Ríos-Bedoya CF, Fernández-Carbia A, Paronetto F, Rodríguez-Orengo JF, Rodríguez-Torres M,. Slower fibrosis progression in HIV/HCV-coinfected patients with successful HIV suppression using antiretroviral therapy. J Hepatol 2006; 44: 47-55. (Pubitemid 41772515)
21. Bonnard P, Lescure FX, Amiel C, Guiard-Schmid JB, Callard P, Gharakhanian S, Pialoux G,. Documented rapid course of hepatic fibrosis between two biopsies in patients coinfected by HIV and HCV despite high CD4 cell count. J Viral Hepat 2007; 14: 806-811. (Pubitemid 47561586)
22. Woitas RP, Rockstroh JK, Beier I, Jung G, Kochan B, Matz B, et al. Antigen-specific cytokine response to hepatitis C virus core epitopes in HIV/hepatitis C virus-coinfected patients. AIDS 1999; 13: 1313-1322. (Pubitemid 29408445)
23. Garba ML, Pilcher CD, Bingham AL, Eron J, Frelinger JA,. HIV antigens can induce TGF-beta(1)-producing immunoregulatory CD8+ T cells. J Immunol 2002; 168: 2247-2254. (Pubitemid 34173033)
24. Safadi R, Ohta M, Alvarez CE, Fiel MI, Bansal M, Mehal WZ, Friedman SL,. Immune stimulation of hepatic fibrogenesis by CD8 cells and attenuation by transgenic interleukin-10 from hepatocytes. Gastroenterology 2004; 127: 870-882. (Pubitemid 39208419)
25. Graham CS, Curry M, He Q, Afdhal N, Nunes D, Fleming C, et al. Comparison of HCV-specific intrahepatic CD4+ T cells in HIV/HCV versus HCV. Hepatology 2004; 40: 125-132. (Pubitemid 38868931)
26. Blackard JT, Komurian-Pradel F, Perret M, Sodoyer M, Smeaton L, St Clair JB, et al. Intrahepatic cytokine expression is downregulated during HCV/HIV co-infection. J Med Virol 2006; 78: 202-207. (Pubitemid 43132564)
27. Shintani Y, Fujie H, Miyoshi H, Tsutsumi T, Tsukamoto K, Kimura S, et al. Hepatitis C virus infection and diabetes: direct involvement of the virus in the development of insulin resistance. Gastroenterology 2004; 126: 840-848. (Pubitemid 38298332)
28. World Health Organization. Hepatitis B. Fact sheet no. 204. Published August 2008. Accessed May 2011.
29. Joint United Nations Programme on HIV/AIDS. HIV and AIDS estimates and data, 2007 and 2001. Accessed May 2011.
30. Thio CL, Seaberg EC, Skolasky R Jr, Phair J, Visscher B, Muñoz A, Thomas DL,; for Multicenter AIDS Cohort Study. HIV-1, hepatitis B virus, and risk of liver-related mortality in the Multicenter Cohort Study (MACS). Lancet 2002; 360: 1921-1926. (Pubitemid 35472132)
31. Bourezane Y, Salard D, Hoen B, Vandel S, Drobacheff C, Laurent R,. DRESS (drug rash with eosinophilia and systemic symptoms) syndrome associated with nevirapine therapy. Clin Infect Dis 1998; 27: 1321-1322. (Pubitemid 29242492)
32. de Maat MM, ter Heine R, van Gorp EC, Mulder JW, Mairuhu AT, Beijnen JH,. Case series of acute hepatitis in a non-selected group of HIV-infected patients on nevirapine-containing antiretroviral treatment. AIDS 2003; 17: 2209-2214. (Pubitemid 37338894)
33. Bossi P, Colin D, Bricaire F, Caumes E,. Hypersensitivity syndrome associated with efavirenz therapy. Clin Infect Dis 2000; 30: 227-228. (Pubitemid 30067101)
34. Laguno M, Milinkovic A, de Lazzari E, Murillas J, Martínez E, Blanco JL, et al. Incidence and risk factors for mitochondrial toxicity in treated HIV/HCV-coinfected patients. Antivir Ther 2005; 10: 423-429. (Pubitemid 41151020)
35. Vrouenraets SM, Treskes M, Regez RM, Troost N, Smulders YM, Weigel HM, et al. Hyperlactataemia in HIV-infected patients: the role of NRTI-treatment. Antivir Ther 2002; 7: 239-244. (Pubitemid 36427127)
36. Maida I, Núñez M, Ríos MJ, Martín-Carbonero L, Sotgiu G, Toro C, et al. Severe liver disease associated with prolonged exposure to antiretroviral drugs. J Acquir Immune Defic Syndr 2006; 42: 177-182. (Pubitemid 43884712)
37. Sandrine PF, Sylvie A, André E, Abdoulaye D, Bernard L, André C,. Nodular regenerative hyperplasia: a new serious antiretroviral drugs side effect? AIDS 2007; 21: 1498-1499. (Pubitemid 46988019)
38. Schiano TD, Kotler DP, Ferran E, Fiel MI,. Hepatoportal sclerosis as a cause of noncirrhotic portal hypertension in patients with HIV. Am J Gastroenterol 2007; 102: 2536-2540. (Pubitemid 47631766)
39. Mallet V, Blanchard P, Verkarre V, Vallet-Pichard A, Fontaine H, Lascoux-Combe C, Pol S,. Nodular regenerative hyperplasia is a new cause of chronic liver disease in HIV-infected patients. AIDS 2007; 21: 187-192. (Pubitemid 46036926)
40. Worm SW, Friis-Møller N, Bruyand M, D'Arminio Monforte A, Rickenbach M, Reiss P, et al.; for D:A:D Study Group. High prevalence of the metabolic syndrome in HIV-infected patients: impact of different definitions of the metabolic syndrome. AIDS 2010; 24: 427-435.
41. Guaraldi G, Squillace N, Stentarelli C, Orlando G, D'Amico R, Ligabue G, et al. Nonalcoholic fatty liver disease in HIV-infected patients referred to a metabolic clinic: prevalence, characteristics, and predictors. Clin Infect Dis 2008; 47: 250-257. (Pubitemid 351920629)
42. Salmon-Ceron D, Rosenthal E, Lewden C, Bouteloup V, May T, Burty C, et al.; for ANRS EN19 Mortalité Study Group and Mortavic. Emerging role of hepatocellular carcinoma among liver-related causes of deaths in HIV-infected patients: the French national Mortalite 2005 study. J Hepatol 2009; 50: 736-745.
43. Bräu N, Fox RK, Xiao P, Marks K, Naqvi Z, Taylor LE,; for North American Liver Cancer in HIV Study Group. Presentation and outcome of hepatocellular carcinoma in HIV-infected patients: a U.S.-Canadian multicenter study. J Hepatol 2007; 47: 527-537. (Pubitemid 47334759)
44. O'Grady J, Taylor C, Brook G,. Guidelines for liver transplantation in patients with HIV infection (2005). HIV Med 2005; 6 (suppl 2): 149-153. (Pubitemid 41038590)
45. McGovern BH, Golan Y, Lopez M, Pratt D, Lawton A, Moore G, et al. The impact of cirrhosis on CD4+ T cell counts in HIV-seronegative patients. Clin Infect Dis 2007; 44: 431-437. (Pubitemid 46147629)
46. Murillas J, Rimola A, Laguno M, de Lazzari E, Rascõn J, Agüero F, et al.; for ESLD-HIV Working Group Investigators. The Model for End-Stage Liver Disease score is the best prognostic factor in human immunodeficiency virus 1-infected patients with end-stage liver disease: a prospective cohort study. Liver Transpl 2009; 15: 1133-1141.
47. de Vera ME, Dvorchik I, Tom K, Eghtesad B, Thai N, Shakil O, et al. Survival of liver transplant patients coinfected with HIV and HCV is adversely impacted by recurrent hepatitis C. Am J Transplant 2006; 6: 2983-2993.
48. Kamath PS, Wiesner RH, Malinchoc M, Kremers W, Therneau TM, Kosberg CL, et al. A model to predict survival in patients with end-stage liver disease. Hepatology 2001; 33: 464-470. (Pubitemid 32119037)
49. Ragni MV, Eghtesad B, Schlesinger KW, Dvorchik I, Fung JJ,. Pretransplant survival is shorter in HIV-positive than HIV-negative subjects with end-stage liver disease. Liver Transpl 2005; 11: 1425-1430. (Pubitemid 43071593)
50. Subramanian A, Sulkowski M, Barin B, Stablein D, Curry M, Nissen N, et al. MELD score is an important predictor of pretransplantation mortality in HIV-infected liver transplant candidates. Gastroenterology 2010; 138: 159-164.
51. Tuma P, Jarrin I, Del Amo J, Vispo E, Medrano J, Martin-Carbonero L, et al. Survival of HIV-infected patients with compensated liver cirrhosis. AIDS 2010; 24: 745-753.
52. Goldberg D, Johnston J, Cameron S, Fletcher C, Stewart M, McMenamin J, et al. Risk of HIV transmission from patients to surgeons in the era of post-exposure prophylaxis. J Hosp Infect 2000; 44: 99-105. (Pubitemid 30120497)
53. Henderson DK,. Postexposure chemoprophylaxis for occupational exposures to the human immunodeficiency virus. JAMA 1999; 281: 931-936. (Pubitemid 29124638)
54. Berenguer M, Royuela A, Zamora J,. Immunosuppression with calcineurin inhibitors with respect to the outcome of HCV recurrence after liver transplantation: results of a meta-analysis. Liver Transpl 2007; 13: 21-29. (Pubitemid 46099970)
55. Frassetto LA, Browne M, Cheng A, Wolfe AR, Roland ME, Stock PG, et al. Immunosuppressant pharmacokinetics and dosing modifications in HIV-1 infected liver and kidney transplant recipients. Am J Transplant 2007; 7: 2816-2820. (Pubitemid 350045781)
56. Tricot L, Teicher E, Peytavin G, Zucman D, Conti F, Calmus Y, et al. Safety and efficacy of raltegravir in HIV-infected transplant patients cotreated with immunosuppressive drugs. Am J Transplant 2009; 9: 1946-1952.
57. Erice A, Rhame FS, Heussner RC, Dunn DL, Balfour HH Jr,. Human immunodeficiency virus infection in patients with solid-organ transplants: report of five cases and review. Rev Infect Dis 1991; 13: 537-547.
58. Mindikoglu AL, Regev A, Magder LS,. Impact of human immunodeficiency virus on survival after liver transplantation: analysis of United Network for Organ Sharing database. Transplantation 2008; 85: 359-368. (Pubitemid 351322759)
59. Neff GW, Bonham A, Tzakis AG, Ragni M, Jayaweera D, Schiff ER, et al. Orthotopic liver transplantation in patients with human immunodeficiency virus and end-stage liver disease. Liver Transpl 2003; 9: 239-247. (Pubitemid 36322325)
60. Ragni MV, Belle SH, Im K, Neff G, Roland M, Stock P, et al. Survival of human immunodeficiency virus-infected liver transplant recipients. J Infect Dis 2003; 188: 1412-1420. (Pubitemid 37523925)
61. Rafecas A, Rufí G, Figueras J, Fabregat J, Ramos E, Xiol X, et al. Liver transplantation in HIV-infected patients [in Spanish]. Gastroenterol Hepatol 2004; 27 (suppl 4): 21-25.
62. Norris S, Taylor C, Muiesan P, Portmann BC, Knisely AS, Bowles M, et al. Outcomes of liver transplantation in HIV-infected individuals: the impact of HCV and HBV infection. Liver Transpl 2004; 10: 1271-1278. (Pubitemid 39406083)
63. Moreno S, Fortún J, Quereda C, Moreno A, Pérez-Elías MJ, Martín-Dávila P, et al. Liver transplantation in HIV-infected recipients. Liver Transpl 2005; 11: 76-81. (Pubitemid 40124445)
64. Schreibman I, Gaynor JJ, Jayaweera D, Pyrsopoulos N, Weppler D, Tzakis A, et al. Outcomes after orthotopic liver transplantation in 15 HIV-infected patients. Transplantation 2007; 84: 697-705. (Pubitemid 47480654)
65. Vennarecci G, Ettorre GM, Antonini M, Santoro R, Perracchio L, Visco G, Santoro E,. Liver transplantation in HIV-positive patients. Transplant Proc 2007; 39: 1936-1938. (Pubitemid 47198836)
66. Duclos-Vallée JC, Féray C, Sebagh M, Teicher E, Roque-Afonso AM, Roche B, et al.; for THEVIC Study Group. Survival and recurrence of hepatitis C after liver transplantation in patients coinfected with human immunodeficiency virus and hepatitis C virus. Hepatology 2008; 47: 407-417. (Pubitemid 351280708)
67. Joshi D, Aluvihare V, Belgaumkar A, Norris S, Heneghan MA, Wendon J, et al. Liver transplantation for HIV: analysis of outcomes suggest HIV/HCV co-infected patients have prohibitively poor survival at 5 years [abstract]. Hepatology 2008; 48 (suppl 1): 311A.
68. Terrault N, Barin B, Schiano TD, Poordad F, Wong M, de Vera ME, et al. Survival and risk of severe hepatitis C virus (HCV) recurrence in liver transplant (LT) recipients coinfected with human immunodeficiency virus (HIV) and HCV [abstract]. Hepatology 2009; 50 (suppl 4): 396A.
69. Gane EJ, Portmann BC, Naoumov NV, Smith HM, Underhill JA, Donaldson PT, et al. Long-term outcome of hepatitis C infection after liver transplantation. N Engl J Med 1996; 334: 815-820. (Pubitemid 26099603)
70. Castells L, Escartín A, Bilbao I, Len O, Allende H, Vargas V, et al. Liver transplantation in HIV-HCV coinfected patients: a case-control study. Transplantation 2007; 83: 354-358.
71. Roland ME, Barin B, Carlson L, Frassetto LA, Terrault NA, Hirose R, et al. HIV-infected liver and kidney transplant recipients: 1- and 3-year outcomes. Am J Transplant 2008; 8: 355-365.
72. Di Benedetto F, Di Sandro S, De Ruvo N, Berretta M, Montalti R, Guerrini GP, et al. Human immunodeficiency virus and liver transplantation: our point of view. Transplant Proc 2008; 40: 1965-1971.
73. Bhagat V, Foont JA, Schiff ER, Regev A,. Spontaneous clearance of hepatitis C virus after liver transplantation in two patients coinfected with hepatitis C virus and human immunodeficiency virus. Liver Transpl 2008; 14: 92-95. (Pubitemid 351167994)
74. Castells L, Esteban JI, Bilbao I, Vargas V, Allende H, Ribera E, et al. Early antiviral treatment of hepatitis C virus recurrence after liver transplantation in HIV-infected patients. Antivir Ther 2006; 11: 1061-1070. (Pubitemid 44955182)
75. Wojcik K, Vogel M, Voigt E, Speidel N, Kalff JC, Goldmann G, et al. Antiviral therapy for hepatitis C virus recurrence after liver transplantation in HIV-infected patients: outcome in the Bonn cohort. AIDS 2007; 21: 1363-1365. (Pubitemid 46883493)
76. Mira JA, Lõpez-Cortés LF, Barreiro P, Tural C, Torres-Tortosa M, de Los Santos Gil I, et al. Efficacy of pegylated interferon plus ribavirin treatment in HIV/hepatitis C virus co-infected patients receiving abacavir plus lamivudine or tenofovir plus either lamivudine or emtricitabine as nucleoside analogue backbone. J Antimicrob Chemother 2008; 62: 1365-1373.
77. Lafeuillade A, Hittinger G, Chadapaud S,. Increased mitochondrial toxicity with ribavirin in HIV/HCV coinfection. Lancet 2001; 357: 280-281. (Pubitemid 32120863)
78. Terrault NA, Carter JT, Carlson L, Roland ME, Stock PG,. Outcome of patients with hepatitis B virus and human immunodeficiency virus infections referred for liver transplantation. Liver Transpl 2006; 12: 801-807.
79. Gazzard BG, Anderson J, Babiker A, Boffito M, Brook G, Brough G, et al.; for BHIVA Treatment Guidelines Writing Group. British HIV Association guidelines for the treatment of HIV-1-infected adults with antiretroviral therapy 2008. HIV Med 2008; 9: 563-608.
80. Tateo M, Roque-Afonso AM, Antonini TM, Medja F, Lombes A, Jardel C, et al. Long-term follow-up of liver transplanted HIV/hepatitis B virus coinfected patients: perfect control of hepatitis B virus replication and absence of mitochondrial toxicity. AIDS 2009; 23: 1069-1076.
81. Coffin CS, Stock PG, Dove LM, Berg CL, Nissen NN, Curry MP, et al. Virologic and clinical outcomes of hepatitis B virus infection in HIV-HBV coinfected transplant recipients. Am J Transplant 2010; 10: 1268-1275.
82. Vogel M, Voigt E, Schäfer N, Goldmann G, Schwarz N, Kalff JC, et al. Orthotopic liver transplantation in human immunodeficiency virus (HIV)-positive patients: outcome of 7 patients from the Bonn cohort. Liver Transpl 2005; 11: 1515-1521. (Pubitemid 43072627)
83. Cargnel A, Angeli E, Mainini A, Gubertini G, Giorgi R, Schiavini M, Duca P,; for Italian Co-Infection Study (ICOS) Group. Open, randomized, multicentre Italian trial on PEG-IFN plus ribavirin versus PEG-IFN monotherapy for chronic hepatitis C in HIV-coinfected patients on HAART. Antivir Ther 2005; 10: 309-317. (Pubitemid 41151037)
84. Torriani FJ, Rodriguez-Torres M, Rockstroh JK, Lissen E, Gonzalez-García J, Lazzarin A, et al.; for APRICOT Study Group. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection in HIV-infected patients. N Engl J Med 2004; 351: 438-450. (Pubitemid 38988593)
85. Laguno M, Cifuentes C, Murillas J, Veloso S, Larrousse M, Payeras A, et al. Randomized trial comparing pegylated interferon alpha-2b versus pegylated interferon alpha-2a, both plus ribavirin, to treat chronic hepatitis C in human immunodeficiency virus patients. Hepatology 2009; 49: 22-31.
86. Chung RT, Andersen J, Volberding P, Robbins GK, Liu T, Sherman KE, et al.; for AIDS Clinical Trials Group A5071 Study Team. Peginterferon alfa-2a plus ribavirin versus interferon alfa-2a plus ribavirin for chronic hepatitis C in HIV-coinfected persons. N Engl J Med 2004; 351: 451-459. (Pubitemid 38988594)
87. Carrat F, Bani-Sadr F, Pol S, Rosenthal E, Lunel-Fabiani F, Benzekri A, et al.; for ANRS HCO2 RIBAVIC Study Team. Pegylated interferon alfa-2b vs standard interferon alfa-2b, plus ribavirin, for chronic hepatitis C in HIV-infected patients: a randomized controlled trial. JAMA 2004; 292: 2839-2848. (Pubitemid 39628231)
88. Moreno A, Bárcena R, García-Garzõn S, Moreno L, Quereda C, Muriel A, et al. Viral kinetics and early prediction of nonresponse to peg-IFN-alpha-2b plus ribavirin in HCV genotypes 1/4 according to HIV serostatus. J Viral Hepat 2006; 13: 466-473.
89. Beresford B,. South Africa pioneers HIV-positive transplants. Published October 25, 2008. Accessed May 2011.